The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of decitabine and carboplatin in recurrent platinum (Pt)-resistant ovarian cancer (OC).
D. Matei
No relevant relationships to disclose
C. Shen
No relevant relationships to disclose
F. Fang
No relevant relationships to disclose
J. Schilder
No relevant relationships to disclose
M. Li
No relevant relationships to disclose
A. Arnold
No relevant relationships to disclose
Y. Zeng
No relevant relationships to disclose
J. M. Pilrose
No relevant relationships to disclose
C. Kulesavage
No relevant relationships to disclose
C. Balch
No relevant relationships to disclose
W. Berry
No relevant relationships to disclose
P. Wulfridge
No relevant relationships to disclose
T. H. Huang
No relevant relationships to disclose
K. P. Nephew
Consultant or Advisory Role - SuperGen
Honoraria - SuperGen